Compare Cassava Sciences Inc (FLNA) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Vistra Corp — how do they compare? Cassava Sciences Inc trades at $1.08 (market cap $53.14M), while Vistra Corp trades at $151.3 (market cap $54.03B). The key difference: Vistra Corp is far larger — about 1016.7× Cassava Sciences Inc's market cap, and Vistra Corp pays a 0.57% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | VST | |
|---|---|---|
Market Cap | $53.14M | $54.03B |
Sector | Health | Technology |
52-Week High | $4.64 | $217.92 |
52-Week Low | $1.09 | $134.71 |
Enterprise Value | -$33.43M | $75.78B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Vistra Corp. (VST) trades at $152.50, down 3.74% amid broader market volatility, but maintains strong analyst support with a 90.91% buy rating. The stock shows bullish technical signals with support at $148 and resistance at $165, while fundamentals reveal robust profitability with 11.52% net income margin and 74.92% ROE. Recent earnings beat expectations in Q1 2026, and the company benefits from long-term power purchase agreements with major tech firms.
Outlook remains positive given Vistra's strategic focus on renewables and AI-driven power demand, though investors face risks from power-price volatility and high debt. The consensus price target of $253.00 implies significant upside potential, supported by institutional confidence and resilient cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
